Q-omics provides the consensus-scored CCT8L1P profile across patient tissues and cancer cell-line models. CCT8L1P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, CCT8L1P is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, CCT8L1P RNA expression shows 11,543 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, KICH, and UVM as cancer lineages where CCT8L1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT8L1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT8L1P survival associations across molecular data types. CCT8L1P RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT8L1P RNA expression–survival associations across cancer types. High CCT8L1P expression shows unfavorable associations in READ, COAD, ACC and LUAD, but favorable associations in BLCA and UCS. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for CCT8L1P RNA expression.
This table summarizes CCT8L1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCT8L1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT8L1P shows lower tumor expression in KICH, BRCA, ESCA, BLCA and KIRC and higher tumor expression in KIRP. The KICH box plot shows higher CCT8L1P RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .005).
This table shows molecular features associated with CCT8L1P in patient tissues and cancer cell lines. In patient samples, CCT8L1P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
